Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -294.91% is 27% below its 5-year average of -232.42%, near the high end of its 5-year range (-1387.99%–0.00%).
4.49% above its 12-month average of -308.78%.
Reported quarterly profit margin; no daily interpolation. Q4 FY2026 (2026-06-30): -341.04%.
NET PROFIT MARGIN
-294.91%
NET PROFIT MARGIN AVG TTM
-308.78%
NET PROFIT MARGIN AVG 3Y
-323.12%
NET PROFIT MARGIN AVG 5Y
-232.42%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.49%
CURRENT VS 3Y AVG
+8.73%
CURRENT VS 5Y AVG
-26.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 698 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Intelligent Bio Solutions Inc.
Market Cap
$5.27M
Net Profit Margin
-294.91%
TTM Avg
-308.78%
3Y Avg
-323.12%
5Y Avg
-232.42%
Market Cap
$5.24M
Net Profit Margin
0.00%
TTM Avg
-61.23%
3Y Avg
-156.55%
5Y Avg
-194.88%
Market Cap
$5.21M
Net Profit Margin
-612568.11%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.29M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.19M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
Market Cap
$5.17M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.20M
Net Profit Margin
-106.78%
TTM Avg
-43.08%
3Y Avg
-12.30%
5Y Avg
-12.30%
Market Cap
$5.14M
Net Profit Margin
-4011.86%
TTM Avg
-2005.93%
3Y Avg
-2671.67%
5Y Avg
-1781.12%
Market Cap
$4.72M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.27M | -294.91% | -308.78% | -323.12% | -232.42% |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | 0.00% | -61.23% | -156.55% | -194.88% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | -612568.11% | 0.00% | 0.00% | 0.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Imunon, Inc. (IMNN)vs › | $5.19M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.20M | -106.78% | -43.08% | -12.30% | -12.30% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.14M | -4011.86% | -2005.93% | -2671.67% | -1781.12% |
| CalciMedica, Inc. (CALC)vs › | $4.72M | 0.00% | 0.00% | 0.00% | 0.00% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-305.0%
Net Profit Margin
-294.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -341.04% |
| 2026-03-31 | -269.86% |
| 2025-12-31 | -298.58% |
| 2025-09-30 | -268.30% |
| 2025-06-30 | -366.13% |
| 2025-03-31 | -348.97% |
| 2024-12-31 | -370.29% |
| 2024-09-30 | -307.88% |
| 2024-06-30 | -382.54% |
| 2024-03-31 | -361.46% |
| 2023-12-31 | -257.79% |
| 2023-09-30 | -304.64% |
| 2023-06-30 | -600.03% |
| 2023-03-31 | -1387.99% |
| 2022-12-31 | -117.92% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | -53.06% |
| 2021-03-31 | -9121.65% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | -1935.00% |
| 2020-06-30 | -662.34% |
| 2020-03-31 | 7344.55% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 2791.23% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 325914.52% |
